HRS-6768

HRS-6768 is an investigational **therapeutic radiopharmaceutical** targeting **fibroblast activation protein alpha (FAP)** and is developed for the treatment of advanced solid tumors. It is categorized as a Class 1 Innovative Drug for radioactive therapy and is specifically intended for patients whose tumors are positive for FAP. The drug is currently in early clinical development, with Phase I/II trials evaluating its pharmacokinetics, radiation dosimetry, safety, and preliminary efficacy in oncology patients. No other similar products are approved for marketing as of the current date. HRS-6768 is being developed and trialed in China, with intravenous administration as the primary route. It was initially developed by Tianjin Hengrui Pharmaceutical and is actively managed by Jiangsu Hengrui Medicine/Jiangsu Hengrui Pharmaceuticals[1][3][4][7][9].